AIM: To determine the possible association of the ApoB100 (Xba Ⅰ ), ApoE (Hha Ⅰ ) and CYP7A1 (Bsa Ⅰ ) gene polymorphisms, with the development of cholesterol gallstone disease (GD) in a Mexican population. METHODS:...AIM: To determine the possible association of the ApoB100 (Xba Ⅰ ), ApoE (Hha Ⅰ ) and CYP7A1 (Bsa Ⅰ ) gene polymorphisms, with the development of cholesterol gallstone disease (GD) in a Mexican population. METHODS: The polymorphisms were analyzed by polymerase chain reaction followed by restriction fragment length polymorphism, in two groups matched by ethnicity, age and sex: patients with GD (n = 101) and stone-free control subjects (n = 101). RESULTS: Allelic frequencies in patients and controls were: 34.16% vs 41.58% (P = 0.124) for X+of ApoB-100; 4.46% vs 5.94% (P = 0.501) for E2, 85.64% vs 78.22% (P = 0.052) for E3, 9.90% vs 15.84% (P = 0.075) for E4 of ApoE; and 25.74% vs 27.72% (P = 0.653) for C of CYP7A1. Differences in genotypic frequencies between the studied groups were not significant (P < 0.05). CONCLUSION: These results demonstrated that no association exists between the studied polymorphisms and cholelithiasis in this high prevalent population.展开更多
目的:探讨化石利胆汤对逆行胰胆管造影取石(ERCP)术后胆总管结石患者血液以及血脂中的胆固醇7α羟化酶以及二磷酸葡萄糖醛酸基转移酶的影响。方法:选取90例行ERCP检查且证实胆总管结石并行碎石取石术患者,将其随机分为治疗组及对照组,每...目的:探讨化石利胆汤对逆行胰胆管造影取石(ERCP)术后胆总管结石患者血液以及血脂中的胆固醇7α羟化酶以及二磷酸葡萄糖醛酸基转移酶的影响。方法:选取90例行ERCP检查且证实胆总管结石并行碎石取石术患者,将其随机分为治疗组及对照组,每组45例,治疗组给予常规治疗结合化石利胆汤,对照组予常规治疗,分别比较治疗前以及治疗后第7天、1个月患者血CYP7A1、B-UGT m RNA以及蛋白的表达情况。结果:治疗组服药后第7天、1个月的CYP7A1、B-UGT m RNA表达水平均明显高于治疗前,且与对照组同时期比较明显升高,治疗组服药治疗后第7天的CYP7A1、B-UGT蛋白表达水平明显较治疗前升高,且与对照组同时期比较明显升高,组间比较差异均有统计学意义(P<0.05)。结论:化石利胆汤可上调胆总管结石ERCP术后患者CYP7A1、B-UGT m RNA及其蛋白的表达。展开更多
基金Supported by PROFAPI-UAS and CECYT from Sinaloa, México
文摘AIM: To determine the possible association of the ApoB100 (Xba Ⅰ ), ApoE (Hha Ⅰ ) and CYP7A1 (Bsa Ⅰ ) gene polymorphisms, with the development of cholesterol gallstone disease (GD) in a Mexican population. METHODS: The polymorphisms were analyzed by polymerase chain reaction followed by restriction fragment length polymorphism, in two groups matched by ethnicity, age and sex: patients with GD (n = 101) and stone-free control subjects (n = 101). RESULTS: Allelic frequencies in patients and controls were: 34.16% vs 41.58% (P = 0.124) for X+of ApoB-100; 4.46% vs 5.94% (P = 0.501) for E2, 85.64% vs 78.22% (P = 0.052) for E3, 9.90% vs 15.84% (P = 0.075) for E4 of ApoE; and 25.74% vs 27.72% (P = 0.653) for C of CYP7A1. Differences in genotypic frequencies between the studied groups were not significant (P < 0.05). CONCLUSION: These results demonstrated that no association exists between the studied polymorphisms and cholelithiasis in this high prevalent population.
文摘目的:探讨化石利胆汤对逆行胰胆管造影取石(ERCP)术后胆总管结石患者血液以及血脂中的胆固醇7α羟化酶以及二磷酸葡萄糖醛酸基转移酶的影响。方法:选取90例行ERCP检查且证实胆总管结石并行碎石取石术患者,将其随机分为治疗组及对照组,每组45例,治疗组给予常规治疗结合化石利胆汤,对照组予常规治疗,分别比较治疗前以及治疗后第7天、1个月患者血CYP7A1、B-UGT m RNA以及蛋白的表达情况。结果:治疗组服药后第7天、1个月的CYP7A1、B-UGT m RNA表达水平均明显高于治疗前,且与对照组同时期比较明显升高,治疗组服药治疗后第7天的CYP7A1、B-UGT蛋白表达水平明显较治疗前升高,且与对照组同时期比较明显升高,组间比较差异均有统计学意义(P<0.05)。结论:化石利胆汤可上调胆总管结石ERCP术后患者CYP7A1、B-UGT m RNA及其蛋白的表达。
